Fresenius Medcl Company Profile
✉ Email this page to a colleague
What is the competitive landscape for FRESENIUS MEDCL, and when can generic versions of FRESENIUS MEDCL drugs launch?
FRESENIUS MEDCL has nine approved drugs.
There are three US patents protecting FRESENIUS MEDCL drugs.
There are twenty-one patent family members on FRESENIUS MEDCL drugs in sixteen countries and ninety-two supplementary protection certificates in thirteen countries.
Summary for Fresenius Medcl
International Patents: | 21 |
US Patents: | 3 |
Tradenames: | 22 |
Ingredients: | 5 |
NDAs: | 9 |
Drugs and US Patents for Fresenius Medcl
Expired US Patents for Fresenius Medcl
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Fresenius Medcl | PHOSLO | calcium acetate | CAPSULE;ORAL | 021160-001 | Apr 2, 2001 | 4,870,105 | ⤷ Try a Trial |
Fresenius Medcl | PHOSLO GELCAPS | calcium acetate | CAPSULE;ORAL | 021160-003 | Apr 2, 2001 | 6,576,665 | ⤷ Try a Trial |
Fresenius Medcl | PHOSLO GELCAPS | calcium acetate | CAPSULE;ORAL | 021160-003 | Apr 2, 2001 | 6,875,445 | ⤷ Try a Trial |
Fresenius Medcl | PHOSLO | calcium acetate | TABLET;ORAL | 019976-001 | Dec 10, 1990 | 4,870,105 | ⤷ Try a Trial |
Fresenius Medcl | PHOSLO GELCAPS | calcium acetate | CAPSULE;ORAL | 021160-003 | Apr 2, 2001 | 4,870,105 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for FRESENIUS MEDCL drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | EQ 169 mg calcium | ➤ Subscribe | 2005-05-31 |
➤ Subscribe | Oral Solution | 667 mg/5 mL | ➤ Subscribe | 2013-12-05 |
International Patents for Fresenius Medcl Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Russian Federation | 2463060 | ⤷ Try a Trial |
China | 104095838 | ⤷ Try a Trial |
South Korea | 101553719 | ⤷ Try a Trial |
China | 101522021 | ⤷ Try a Trial |
European Patent Office | 2048948 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Fresenius Medcl Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2957286 | 2018/046 | Ireland | ⤷ Try a Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170719 |
2365988 | CA 2018 00006 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721 |
2822954 | SPC/GB18/031 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM.; REGISTERED: UK EU/1/18/1289/001(NI) 20180625; UK EU/1/18/1289/002(NI) 20180625; UK PLGB 11972/0008 20180625 |
2203431 | 92666 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119 |
2666774 | CR 2020 00037 | Denmark | ⤷ Try a Trial | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.